FDA Now Allows Certain Lab Animals to Be Retired and Adopted

Current bills in Congress would apply similar provisions to all federal agencies.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, NIDERLANDER

The US Food and Drug Administration will now permit certain animals used in experiments to retire and be adopted rather than face euthanasia, according to internal documents reviewed by The Hill. Although the policy changed in November, there have not been any public statements from the agency.

According to The Hill, the FDA used nearly 2,000 animals in medical testing during 2018.

The National Institutes of Health and Veterans Affairs have already adopted policies to rehome retired lab animals. Despite steps taken by individual agencies to rehome animals, there are no mandates that apply to all federally funded research. Currently, there is bipartisan Congressional support for doing so.

House Resolution 2897, named the Animal Freedom from Testing, Experiments, and Research (AFTER) Act of 2019, was introduced to the House of Representatives in May 2019 by Congressman Brendan Boyle (D-PA). This bill would amend the Animal Welfare ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Lisa Winter

    Lisa Winter became social media editor for The Scientist in 2017. In addition to her duties on social media platforms, she also pens obituaries for the website. She graduated from Arizona State University, where she studied genetics, cell, and developmental biology.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio